Tianlong Showcases Innovation at Prestigious International Biomedical Forum in Kazakhstan

KARAGANDA, Kazakhstan, April 22, 2025 /PRNewswire/ -- Tianlong Science and Technology is honored to have been invited to speak at the "International Biomedical Forum: Researches and Innovations", held on April 17–18, 2025, at Karaganda Medical University in Kazakhstan. In addition to presenting at the forum, the Tianlong team also conducted site visits and market research activities in Kazakhstan, further deepening engagement with the local healthcare community.

Co-organized by the Ministry of Health of the Republic of Kazakhstan, the Ministry of Science and Higher Education of the Republic of Kazakhstan, and Karaganda Medical University, this high-level event brought together leading voices from the global biomedical community to discuss cutting-edge research and emerging technologies shaping the future of healthcare.

Representing the innovation strength of our group, Jessica Wu, PhD in Biology and Product Manager of Tianlong, delivered a presentation titled "LigSeq Reagent Kits: Personalized Medication for Better Healthcare". The presentation introduced our latest achievements in precision diagnostics, highlighting how LigSeq technology is supporting more individualized and effective treatment pathways.

We were also proud to share the stage with a distinguished lineup of international experts who offered deep insights into the latest biomedical breakthroughs. Among them were Prof. Luc van der Laan from Erasmus University Medical Center in the Netherlands, and Prof. Florent Dumont of Paris-Saclay University. The forum also featured remarks from Mr. Xavier Le Torrivellec, Education Cooperation Attaché of the French Embassy in Kazakhstan, highlighting international collaboration in biomedical education and research.

The forum's agenda reflected its global vision, covering key topics such as drug development, genomics and proteomics, artificial intelligence in healthcare, and the integration of big data in clinical decision-making. Our participation in this prestigious forum underscores Tianlong's ongoing commitment to advancing global healthcare through innovation, collaboration, and expertise.

Following the successful presentation at the forum, the Tianlong team also visited local healthcare institutions and the Research and Production Center of Transfusion under the Ministry of Health of the Republic of Kazakhstan. During these visits, our team held in-depth exchanges with local medical professionals, discussing current trends and needs in blood screening and transfusion safety.

The visit also included a focused market survey on Kazakhstan's blood screening landscape, enabling our team to gain valuable insights into clinical workflows, diagnostic requirements, and regulatory practices in the country. These findings will serve as a crucial foundation for the future introduction and localization of Tianlong's blood screening solutions.

By engaging directly with local professionals and understanding the Kazakhstani diagnostic market, Tianlong continues to lay the groundwork for meaningful contributions to public health initiatives in Central Asia.

About Tianlong

Tianlong Science and Technology, founded in 1997, is a pioneer in the field of genetic testing and molecular diagnostics. Together with our group company Shanghai Kehua Bio-engineering Co., Ltd. (KHB), we have established five core technology platforms — immunodiagnostics, biochemistry, molecular diagnostics, POCT, and mass spectrometry, specializing in the research, development, and manufacturing of instruments and in vitro diagnostic (IVD) reagents — offering comprehensive solutions across a wide range of sectors, including clinical diagnostics, blood centers, disease control, veterinary epidemic prevention, and food safety.

For more information, please visit Tianlong's official website and its LinkedIn, Facebook, and Twitter pages.

Tianlong Science and Technology

** The press release content is from PR Newswire. Bastille Post is not involved in its creation. **

Tianlong Showcases Innovation at Prestigious International Biomedical Forum in Kazakhstan

Tianlong Showcases Innovation at Prestigious International Biomedical Forum in Kazakhstan

Tianlong Showcases Innovation at Prestigious International Biomedical Forum in Kazakhstan

Tianlong Showcases Innovation at Prestigious International Biomedical Forum in Kazakhstan

AUCKLAND, New Zealand, May 2, 2025 /PRNewswire/ -- Soft tissue regeneration company, Aroa Biosurgery, is pleased to announce a milestone in clinical evidence.

There are now over 100 peer-reviewed studies describing the efficacy of the company's proprietary AROA ECM technology.

AROA's most recent publication was a large retrospective analysis of real-world evidence (RWE) from wound care centers in the US, assessing the efficacy of the company's Endoform Natural^TM product in treating venous leg ulcers (VLUs), in comparison to a leading reconstituted collagen dressing.

VLU's are open sores that are hard-to-heal because of impaired blood flow and can be very debilitating and painful.  These types of wounds are difficult for clinicians to treat successfully. For example, only ~40% of VLUs can be healed after 3 months of treatment and there is a relatively high chance that these wounds will recur^[1].

The peer-reviewed study, entitled "Clinical Efficacy of Ovine Forestomach Matrix and Collagen/Oxidized Regenerated Cellulose for the Treatment of Venous Leg Ulcers: A Retrospective Comparative Real-World Evidence Study" was published in the open access journal 'International Wound Journal in April 2025.

The study compared 470 VLU's that had been treated with Endoform Natural to 360 VLU's that had been treated with a reconstituted collagen product. The study used existing data from 223 wound care centers with minimal inclusion or exclusion criteria so that 'real-world' use of both products could be compared.

"There is a growing awareness of RWE studies to validate clinical performance" says Chief Scientific Officer, Dr. Barnaby May. "These types of studies enable much larger patient numbers to be compared versus traditional randomized controlled trials. Given that RWE studies use data from 'real-world' use of a treatment, the results can be more meaningful, especially in wound care where there is a high degree of variability in how wounds are cared for and patient factors."

The study found that VLUs treated with Endoform Natural healed up to ~ 8 weeks faster versus the comparator group, and the chances of the wound healing were significantly improved when Endoform Natural was used as part of treatment.

The striking difference in the healing outcomes demonstrate the potential for considerable cost reductions and improvements in patient quality of life, due to the significant improvements seen when VLUs were treated using Endoform Natural.

Dr. Gregory Bohn MD was part of the research team. "I was first introduced to Endoform in 2012 and started using the product to treat my own patients with VLUs. This new data validates what I have seen in my own practice managing VLUs with Endoform."

This is the second large retrospective RWE comparing Endoform Natural to a leading reconstituted collagen dressing. A previous study included the analysis of over 2,200 diabetic foot ulcers (DFUs) and also demonstrated significantly faster healing of DFUs using Endoform Natural^[2].

The study is available online here.

[1] Kolluri R, Lugli M, Villalba L, Varcoe R, Maleti O, Gallardo F, et al. An estimate of the economic burden of venous leg ulcers associated with deep venous disease. Vasc Med. 2022;27(1):63-72.

[2] Bosque BA, Frampton C, Chaffin AE, Bohn GA, Woo K, DeLeonardis C, Lepow BD, Melin MM, Madu T, Dowling SG, May BCH. Retrospective real-world comparative effectiveness of ovine forestomach matrix and collagen/ORC in the treatment of diabetic foot ulcers. Int Wound J. 2022 May;19(4):741-753.

** The press release content is from PR Newswire. Bastille Post is not involved in its creation. **

AROA hits evidence milestone with real-world study validating the efficacy of Endoform in treating challenging venous leg ulcers.